ClinicalTrials.gg
RecruitingNCT06831383Updated May 19, 2026

The STOP-HPV Scale Up Study

An interventional study of STOP-HPV-Online and STOP-HPV-LC in Human Papilloma Virus Vaccine, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 9 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100,000
Allocation
Randomized
Ages
9 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Papilloma with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Papilloma · United States.

Planned enrollment
Largest of 39
100,000 · median 155
Started
2026
with 3 others
No phase
27 of 51
5 open now
Primary completion
2027-04
later than 6 of 12 live
Registered
46th of 51
by date

Among the 51 studies in Papilloma with a site in United States, this one has the largest planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2026, is one of 27 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 46th registered.

Papilloma

89 studies on the registry are indexed under Papilloma; 20 are open to participants now.

Browse Papilloma studies →

Open to participants now

9 of the 51 studies in Papilloma with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Papilloma studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 9 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Papilloma with a site in United States, or all of them as a file.
02

Study summary

Human papillomavirus (HPV) causes 35,900 US cancer cases per year, 4,000 deaths, and $4 billion in can In this study, the investigators will conduct a 3-arm clustered randomized controlled trial (RCT) in an estimated 72 practices from up to 8 health systems to evaluate the effectiveness and cost effectiveness of two potentially scalable implementation strategies (based on prior work) to increase the initiation of HPV vaccine against a usual care (control) arm. The intervention arms are 1) online provider communication training only ("STOP-HPV-Online" and 2) online provider communication training plus a Learning Collaborative, with performance feedback, attended by practice leads ("STOP-HPV-LC).

cer-related costs. It is recommended at ages 11-12 years routinely but can be given starting at ages 9-10 years. Despite having an effective vaccine, HPV vaccine initiation/completion rates in the U.S. were only at 76.8%/61.4% respectively in 2023 among 13-17 year olds; these rates are lower than the other recommended adolescent vaccines. Two key barriers are 1) suboptimal clinician communication to address parental concerns and 2) ineffective office systems causing missed vaccine opportunities.

Read the detailed description

In prior work, the investigators have tested two implementation strategies/interventions that were effective, but which were deployed by the research team. The first is provider communication training ("STOP-HPV-Online"), delivered by the research team, in a cluster RCT in 48 pediatric practices from a research network (6.8% improvement in initiation). The other is a quality improvement, pre-post study, that included both provider communication training, as well as a Learning Collaborative (LC) for practice leads (8% increase in initiation).

A major challenge in implementation science and spreading practice-based strategies is to move from research teams deploying implementation strategies (intervention) to health systems deploying them. In this study, the investigators will compare the effectiveness and cost-effectiveness of the two implementation strategies (interventions) using a 3-arm clustered RCT: 1) STOP-HPV-Online vs 2) STOP-HPV-LC vs 3) usual care. The study team will randomize an estimated 72 practices (from up to 8 health systems) to the 1) STOP-HPV-Online arm, 2) the STOP-HPV-LC arm or 3) the control arm, assess fidelity to the intervention and conduct the evaluation. A collaborating organization, AMGA (the American Medical Group Association), will facilitate training of the health system personnel, as needed; however, the health systems will deploy each intervention. The primary outcome measure is the initiation rate among 9-\<13 year olds with a well-child care visit during the 12 month intervention period (with inclusion starting at the time of a well child care visit during the intervention period). A secondary outcome measure will be the initiation rate among 13-17 year olds with a well child care visit during the intervention period (with inclusion starting at the time of a well child care visit during the intervention period. For both measures, inclusion criteria will be: 1) presenting to a participating practice, 2) age eligible at the visit and 3) no prior vaccine at the time of the visit.

03

Conditions studied

  • Human Papilloma Virus Vaccine

Browse trials for

Keywords

  • Human Papillomavirus Vaccination
  • Practice-based improvement
04

Who can participate

Ages eligible
9 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient of participating practice
  • Well child care visit during the 12-month intervention period
  • No prior dose of HPV vaccine at the time of the well child care visit
  • Age-eligible

Exclusion criteria

Exclusion Criteria:

  • Prior dose of HPV vaccine
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100,000 participants (estimated)

Study arms

  • Experimental
    STOP-HPV Online

    Provider communication training

    Behavioral: STOP-HPV-Online

  • Experimental
    STOP-HPV LC

    Provider communication training plus Learning Collaborative sessions attended by practice leads and quarterly performance feedback to the practice.

    Behavioral: STOP-HPV-LC

  • No intervention
    Usual Care

    Standard of care control

Interventions

  • BehavioralSTOP-HPV-Online

    Approximately one third of practices within a participating health system will be randomized to receiving the STOP-HPV-Online intervention.

  • BehavioralSTOP-HPV-LC

    Approximately one third of practices within a participating health system will be randomized to receiving the STOP-HPV-LC intervention.

06

What researchers measure

Primary outcomes

  1. Initiation (first dose) of HPV vaccination among 9-<13 year olds at or following a well care visit with a participating provider during the intervention period.

    The percent of children ages 9-\<13 years of age who received their first dose of HPV vaccine at or following a well child care visit with a participating provider during the intervention-period (denominator is children ages 9-\<13 with a well child visit during the study period at which they were due for their first dose).

    Time frame: 12 months from start of intervention

Secondary outcomes

  1. Initiation (first dose) of HPV vaccination among 13-17 year olds at or following a well care visit with a participating provider during the intervention period.

    The percent of children ages 13-17 years of age who received their first dose of HPV vaccine at or following a well child care visit with a participating provider during the intervention-period (denominator is children ages 13-17 years with a well child visit during the study period at which they were due for their first dose).

    Time frame: 12 months from start of intervention

  2. Initiation (first dose) of HPV vaccination among 9-<13 year olds at or following a well care visit with any provider during the intervention period.

    The percent of children ages 9-\<13 years of age who received their first dose of HPV vaccine at or following a well child care visit with any provider (participating or not) during the intervention-period (denominator is children ages 9-\<13 with a well child visit during the study period at which they were due for their first dose).

    Time frame: 12 months from start of intervention

  3. Initiation (first dose) of HPV vaccination among 13-17 year olds at or following a well care visit with any provider during the intervention period.

    The percent of children ages 13-17 years of age who received their first dose of HPV vaccine at or following a well child care visit with any provider (participating or not) during the intervention-period (denominator is children ages 13-17 years with a well child visit during the study period at which they were due for their first dose).

    Time frame: 12 months from start of intervention

  4. Total implementation cost

    The difference in costs between arms will be used to calculate the incremental cost-effectiveness ratio (ICER)

    Time frame: 12 months from start of intervention

07

Study locations

1 of 1 sites recruiting
  • AMGA
    Alexandria, Virginia 22314, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.

Of 28 interventional studies with no phase under Papilloma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2025
First posted
Feb 18, 2025
StartActual
Mar 30, 2026
Primary completionEst.
Apr 19, 2027
CompletionEst.
Apr 19, 2027
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06831383
Collaborators
American Medical Group Association, National Cancer Institute (NCI)
Responsible party
Peter G Szilagyi, MD MPH (Professor, University of California, Los Angeles) — Principal investigator
First posted
Feb 18, 2025
Start date
Mar 30, 2026
Primary completion
Apr 19, 2027 (estimated)
Completion
Apr 19, 2027 (estimated)
Last update
May 19, 2026

Study contacts

Peter Szilagyi, MD, MPH
Contact
pszilagyi@mednet.ucla.edu
310-206-6328
Christina Albertin, PhD, MPH
Contact
calbertin@mednet.ucla.edu
317-701-4926
Peter Szilagyi, MD, MPH
principal investigator · University of California, Los Angeles

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion